Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
Aytu BioPharma (NASDAQ:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has scheduled its fiscal 2025 full year and fourth quarter financial results announcement for September 23, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. Eastern time on the same day, featuring a results review and Q&A session. The call will be accessible via phone and webcast, with replay available until October 7, 2025.
Aytu BioPharma (NASDAQ:AYTU), un'azienda farmaceutica specializzata in medicinali innovativi per malattie complesse del sistema nervoso centrale, ha programmato la pubblicazione dei risultati finanziari per l'anno fiscale 2025 completo e il quarto trimestre per il 23 settembre 2025, dopo la chiusura del mercato.
L'azienda terrà una conference call e una webcast alle 16:30 ora dello Stato dell'Est nello stesso giorno, con una revisione dei risultati e una sessione di domande e risposte. La chiamata sarà accessibile sia telefonicamente che via webcast, con la replica disponibile fino al 7 ottobre 2025.
Aytu BioPharma (NASDAQ:AYTU), una empresa farmacéutica especializada en medicamentos innovadores para enfermedades complejas del sistema nervioso central, ha programado la publicación de sus resultados financieros para el año fiscal 2025 completo y el cuarto trimestre para el 23 de septiembre de 2025, después del cierre del mercado.
La empresa organizará una conferencia telefónica y una webcast a las 16:30 hora del Este en el mismo día, con una revisión de resultados y una sesión de preguntas y respuestas. La llamada estará disponible por teléfono y vía webcast, con la repetición disponible hasta el 7 de octubre de 2025.
Aytu BioPharma (NASDAQ:AYTU), 복합 중추 신경계 질환에 대한 혁신 의약품을 전문으로 하는 제약 회사는 2025 회계연도 전체 연도 및 4분기 재무 결과 발표를 2025년 9월 23일에 장 마감 후로 예정했습니다.
동일한 날에 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 개최하여 실적 검토 및 질의응답 세션이 진행됩니다. 전화와 웹캐스트를 통해 접속 가능하며 2025년 10월 7일까지 재방송이 제공됩니다.
Aytu BioPharma (NASDAQ:AYTU), une société pharmaceutique spécialisée dans des médicaments innovants pour des maladies complexes du système nerveux central, a prévu d’annoncer ses résultats financiers pour l’année fiscale 2025 complète et le quatrième trimestre le 23 septembre 2025, après la clôture du marché.
La société animera une conférence téléphonique et une webcast à 16h30, heure de l’Est le même jour, avec un tour d’horizon des résultats et une session de questions-réponses. L’appel sera accessible par téléphone et par webcast, avec une rediffusion disponible jusqu’au 7 octobre 2025.
Aytu BioPharma (NASDAQ:AYTU), ein auf innovative Medikamente für komplexe Erkrankungen des zentralen Nervensystems spezialisiertes Pharmaunternehmen, hat die Veröffentlichung der finanziellen Ergebnisse für das gesamte Geschäftsjahr 2025 und das vierte Quartal auf 24. September 2025 festgelegt, nach Börsenschluss.
Am selben Tag wird das Unternehmen eine Telefon- und Webkonferenz um 16:30 Uhr Eastern Time abhalten, mit einer Ergebnisübersicht und einer Q&A-Sitzung. Der Anruf ist sowohl telefonisch als auch via Webcast zugänglich, die Wiederholung ist bis zum 7. Oktober 2025 verfügbar.
Aytu BioPharma (NASDAQ:AYTU)، شركة أدوية تتخصص في أدوية مبتكرة لاضطرابات الجهاز العصبي المركزي المعقدة، حددت إعلان نتائجها المالية للسنة المالية 2025 كاملة والربع الرابع في 23 سبتمبر 2025، بعد إغلاق السوق.
ستستضيف الشركة مكالمة هاتفية وبثًا مباشرًا على الويب في الساعة 4:30 مساءً بتوقيت الساحل الشرقي في اليوم نفسه، مع مراجعة النتائج وجلسة أسئلة وأجوبة. ستكون المكالمة متاحة عبر الهاتف والويب بث، مع إمكانية إعادة البث حتى 7 أكتوبر 2025.
Aytu BioPharma (NASDAQ:AYTU)，一家专注于中枢神经系统复杂疾病创新药物的制药公司，已将<缺失标题>2025财政年度全年度及第四季度业绩公告定于2025年9月23日收盘后公布。
该公司将于同日举行< b>美东时间下午4:30的电话会议和网络广播，进行业绩回顾与问答环节。此次电话会议可通过电话和网络广播接入，回放将持续至2025年10月7日。
- None.
- None.
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on Tuesday, September 23, 2025. The Company has scheduled a conference call and webcast that same day, Tuesday, September 23, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Tuesday, September 23, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 447137.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/52803, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until October 7, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 52803.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Aytu BioPharma (AYTU) report its fiscal 2025 earnings?
How can investors access Aytu BioPharma's Q4 2025 earnings call?
What time is Aytu BioPharma's Q4 2025 earnings conference call?
How long will Aytu BioPharma's Q4 2025 earnings call replay be available?
